Does Higher pCR Come at a Cost? Weighing Efficacy vs Toxicity in DB-11

DB-11 showed higher pathologic complete response rates — but with important trade-offs.

This clip examines toxicity, monitoring burden, financial considerations, and why substituting trastuzumab deruxtecan for anthracyclines poses new clinical and practical questions in the neoadjuvant setting.